The Neupro recall means that patients need to be switched from the patch to an oral dopamine agonist
May 2008
The Neupro recall means that patients need to be switched from the patch to an oral dopamine agonist.
Neupro (rotigotine) was heralded as a big advance last year as the first patch for Parkinson's disease. It's a dopamine agonist similar to Mirapex (pramipexole) and Requip (ropinirole).
Now the patches are being recalled because of problems with crystals forming which could decrease drug delivery.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote